This federal Project Grant award, valued at $415,902 and issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at overcoming therapy resistance and lineage plasticity in castration-resistant prostate cancer. The award to the University of Massachusetts Boston will fund investigations into how the transcription factor FOXA2, in collaboration with AP-1, drives prostate cancer cells into an adaptive multilineage...
This $371,719 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to characterize epigenetic targets, specifically the histone methyltransferase NSD2, and their role in driving the oncogenic androgen receptor (AR) transcriptional program in prostate cancer. The research, to be conducted by the University of Pennsylvania, has two main objectives:
Gain deeper molecular insights into how NSD2 influences the chromatin landscape to...
The National Cancer Institute awarded a $627,474 Project Grant under its Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Dana-Farber Cancer Institute in Boston, Massachusetts. The grant will fund a 5-year research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative...
This federal Project Grant award of $1,082,472 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to determine the molecular mechanisms underlying the transition of prostate cancer from a luminal to a neuroendocrine phenotype. The primary objectives are to investigate how the transcription factors FOXA2 and NKX2-1 interact to drive this "luminal-to-neuroendocrine transdifferentiation" process, and to evaluate the role...
This National Cancer Institute (CFDA 93.396 - Cancer Biology Research) Project Grant award to Yale University for $1,217,802 will support research to decipher the impact of ZNF397 deficiency in promoting TET2-driven epigenetic rewiring, lineage plasticity, and therapy resistance in prostate cancer. The research aims to comprehensively assess the effect of ZNF397 deficiency on prostate cancer tumorigenesis, therapy responsiveness, and lineage plasticity, elucidate the molecular mechanism of...
This $421,042 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports a study of IDH1-mutant prostate cancer to identify novel therapeutic targets. The primary objectives are to investigate the mechanisms by which IDH1-mutant prostate cancer fails to acquire resistance to therapy, with the goal of identifying new treatment approaches to prevent resistance development. The study will involve analyzing clinical, genomic,...
This $564,543 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in prostate cancer. The key objectives are to:
Determine the conditions that allow engagement of the AR's growth-suppressive transcriptional programs in prostate cancer cells, which could be leveraged to inhibit tumor growth.
Establish the...
This $447,340 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to improve the survival rate of patients with metastatic, endocrine-resistant breast cancer. The primary objectives are to investigate epigenetic vulnerabilities and identify new therapeutic targets related to the CoREST-SWI/SNF axis in breast cancer cells with estrogen receptor (ER) mutations or SWI/SNF gene mutations. This 5-year research project, with a start date of March 1,...
This $392,410 National Cancer Institute (NCI) Project Grant award, issued under the Cancer Research Manpower program (CFDA 93.398), supports research at Weill Medical College of Cornell University to investigate the drivers of tumor heterogeneity and the progression to neuroendocrine prostate cancer (NEPC). The 3-year project will use novel genetically-engineered mouse models and organoid-based platforms to study the role of a previously undescribed tumor subpopulation in the transition from...
This $538,553 project grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund a longitudinal study to investigate the use of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of treatment outcomes for prostate cancer patients receiving radiotherapy with androgen deprivation therapy (RT+ADT).
The key objectives are to: 1) define the role of mpMRI habitat risk score features in...
This $832,818 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research by the University of Massachusetts Boston to elucidate the non-canonical tumor-suppressive role of the epigenetic regulator SETD7 in prostate cancer progression and treatment resistance.
The key objectives are to: 1) Assess SETD7 protein expression and its correlation with other epigenetic regulators in castration-resistant prostate cancer (CRPC) specimens, 2) Delineate the mechanisms by which SETD7 restricts the chromatin binding of the pioneer factor FOXA1 to prevent transcriptional reprogramming, and 3) Evaluate treatment strategies targeting vulnerabilities induced by SETD7 deficiency in CRPC models.
This 5-year project aims to enhance understanding of SETD7's role in prostate cancer and identify new therapeutic approaches for the aggressive SETD7-deficient CRPC subtype. The research will be conducted at the University of Massachusetts Boston.